Version 1
: Received: 31 October 2024 / Approved: 31 October 2024 / Online: 1 November 2024 (08:11:42 CET)
How to cite:
Pleshkan, V. V.; Kondratyeva, L. G.; Zinovyeva, M. V.; Alekseenko, I. V. Bacillus Calmette-Guérin (BCG) – A Landscape of Utility. Preprints2024, 2024110025. https://doi.org/10.20944/preprints202411.0025.v1
Pleshkan, V. V.; Kondratyeva, L. G.; Zinovyeva, M. V.; Alekseenko, I. V. Bacillus Calmette-Guérin (BCG) – A Landscape of Utility. Preprints 2024, 2024110025. https://doi.org/10.20944/preprints202411.0025.v1
Pleshkan, V. V.; Kondratyeva, L. G.; Zinovyeva, M. V.; Alekseenko, I. V. Bacillus Calmette-Guérin (BCG) – A Landscape of Utility. Preprints2024, 2024110025. https://doi.org/10.20944/preprints202411.0025.v1
APA Style
Pleshkan, V. V., Kondratyeva, L. G., Zinovyeva, M. V., & Alekseenko, I. V. (2024). Bacillus Calmette-Guérin (BCG) – A Landscape of Utility. Preprints. https://doi.org/10.20944/preprints202411.0025.v1
Chicago/Turabian Style
Pleshkan, V. V., Marina V. Zinovyeva and Irina V. Alekseenko. 2024 "Bacillus Calmette-Guérin (BCG) – A Landscape of Utility" Preprints. https://doi.org/10.20944/preprints202411.0025.v1
Abstract
As one of the first live vaccines, Bacillus Calmette-Guérin (BCG) is experiencing a experiencing its second rise. The recent COVID-19 pandemic has spurred interest in BCG due to its ability to provide protection not only against mycobacteria, but also against unrelated pathogens. This ability is based on BCG's ability to non-specifically activate cells of the innate immune system, bringing them into a prepared state where they can be activated more quickly. The process known as trained immunity. This ability of BCG to elicit an immune response gives it the opportunity to become not only a basis for universal or pan-pandemic vaccines, but also a cancer vaccine. We have reviewed the main mechanisms underlying the immunoactivating effect of BCG and proposed ways to enhance this effect. Since the pandemic has greatly altered the research landscape in vaccinology and, to some extent, cancer immunotherapy, we have focused more on studies published during and after the pandemic, minimizing information from the pre-pandemic period where possible. We discuss the recent trend in the use of BCG-based therapies, with particular emphasis on ongoing clinical trials. Based on the data presented, we suggested the most optimal options for further research to develop effective BCG-based vaccines.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
